Temozolomide-d3

Modify Date: 2024-01-03 18:39:17

Temozolomide-d3 Structure
Temozolomide-d3 structure
Common Name Temozolomide-d3
CAS Number 208107-14-6 Molecular Weight 197.16900
Density 2.004g/cm3 Boiling Point 526.592ºC at 760 mmHg
Molecular Formula C6H3D3N6O2 Melting Point 202-204ºC
MSDS N/A Flash Point 272.273ºC

 Use of Temozolomide-d3


Temozolomide-d3 (NSC 362856-d3) is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].

 Names

Name 4-oxo-3-(trideuteriomethyl)imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
Synonym More Synonyms

 Temozolomide-d3 Biological Activity

Description Temozolomide-d3 (NSC 362856-d3) is the deuterium labeled Temozolomide. Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects[1][2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.

[3]. Mathieu V, et al. Combining Anti-Human VEGF with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008 Dec;10(12):1383-92.

[4]. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131.

 Chemical & Physical Properties

Density 2.004g/cm3
Boiling Point 526.592ºC at 760 mmHg
Melting Point 202-204ºC
Molecular Formula C6H3D3N6O2
Molecular Weight 197.16900
Flash Point 272.273ºC
Exact Mass 197.07400
PSA 108.17000
Vapour Pressure 0mmHg at 25°C
Index of Refraction 1.895

 Synonyms

Temodar-d3
Methazolastone-d3
Temozolomide-d3
Temodal-d3